Will the Covid-19 vaccine change the long-term trends?

Equities 4 minutes to read

Peter Garnry

Head of Equity Strategy

Summary:  In today's equity update we take a look at the market reaction to the news from Pfizer announcing great results on its Covid-19 vaccine. Good news has been bad news for the markets with many trades reversing causing a big jolt to momentum and technology stocks. However, is this short-term reaction the start of something longer term with value outperforming growth/momentum, or European equities suddenly outperforming US equities? In our view the long trend since 2009 is not broken and technology stocks will continue to deliver the best risk-reward ratio for long-term investors. The key risk is obviously where interest rates go as growth stocks are more sensitive to interest rates.


The news yesterday from Pfizer announcing that its Covid-19 vaccine is 90% effective significantly exceeding the market expectations of 60-70% gave a big jolt to equity markets. S&P 500 jumped more than 3% on the news driven by the energy, financials, and industrials sectors. Sitting opposite this reaction function was technology stocks with the Nasdaq 100 futures correcting significantly lower with the weakness extending in today’s session. As the chart below shows, European equities are benefitting the most from the vaccine as the European economy is hit hard from Covid-19 and generally European equities are more cyclical than the overall US equity markets.

Source: Bloomberg

The market reaction over the past 48 hours beg the question whether many of the assumptions among investors are wrong and whether many “obvious” trades will reverse over a longer period. If one zooms out the Covid-19 and the vaccine news could suddenly give the impression that technology stocks are not worth owning any longer. But looking at it from a longer time perspective US technology stocks have had explosive earnings growth since 2009 while also being more immune to crises such as the euro area crisis in 2011-2012, emerging markets and USD in 2015, and lately Covid-19. This long-term trend will not change because of a vaccine and thus investors will likely revert to the same conclusion which is that this is the fastest growing segment of the market and where the future lies. We remain positive and overweight the technology segment and still sceptical of European equities still dominated by financials. The key risk to our positive view on technology stocks over the next year is rising interest rates which will have larger negative impact on growth stocks than value stocks.

In the short-term a lot views will LAO be updated for the travel and leisure segment across the world. The table below shows the general positive price action today in Europe across this hard-hit segment. Due to the vaccine uncertainty in terms of safety and delivery this segment will likely experience a lot of volatility in the coming months providing excellent trading opportunities.

Source: Bloomberg

The chart below is for regulatory purposes

Source: Bloomberg

Disclaimer

The Saxo Bank Group entities each provide execution-only service and access to Analysis permitting a person to view and/or use content available on or via the website. This content is not intended to and does not change or expand on the execution-only service. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Bank Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Bank Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Bank Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Bank Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.

Please read our disclaimers:
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)
- Full disclaimer (https://www.home.saxo/en-gb/legal/disclaimer/saxo-disclaimer)

Trade Responsibly
All trading carries risk. To help you understand the risks involved we have put together a series of Key Information Documents (KIDs) highlighting the risks and rewards related to each product. Read more
Additional Key Information Documents are available in our trading platform.

Saxo Markets is a registered Trading Name of Saxo Capital Markets Ltd (‘SCML’). SCML is authorised and regulated by the Financial Conduct Authority, Firm Reference Number 551422. Registered address: 26th Floor, 40 Bank Street, Canary Wharf, London E14 5DA. Company number 7413871.

This website, including the information and materials contained in it, are not directed at, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in the United States, Belgium or any other jurisdiction where such distribution, publication, availability or use would be contrary to applicable law or regulation.

It is important that you understand that with investments, your capital is at risk. Past performance is not a guide to future performance. It is your responsibility to ensure that you make an informed decision about whether or not to invest with us. If you are still unsure if investing is right for you, please seek independent advice. Saxo Markets assumes no liability for any loss sustained from trading in accordance with a recommendation.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc. Android is a trademark of Google Inc.